Supriya Lifescience, an ugly duckling stock idea

The closure of china market due to covid lockdowns has hampered its export sales in FY 22-23... One is expecting trend reversal backed by encouraging Q4 results... promoter purchased shares from open market in march quarter... with china ports having opened from Nov22 it is estimated that export shipments to the china market (which the company is heavily dependent on) has been normalized by Q4... results and operating margins will confirm the thesis.. share price tradng above 225 looks a good zone to accmulate imho.

Kommentera:

Results on 27 May, its a weekend, this will aid or break the thesis...